The Tribble with APL: a new road to therapy

Carmody, R. and Keeshan, K. (2017) The Tribble with APL: a new road to therapy. Cancer Cell, 31(5), pp. 612-613. (doi: 10.1016/j.ccell.2017.04.011) (PMID:28486101)

140027.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL). Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance. Targeting the interaction of TRIB3 and PML-RARα using peptide technology provides a novel therapeutic approach.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Carmody, Dr Ruaidhri and Keeshan, Dr Karen
Authors: Carmody, R., and Keeshan, K.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Cancer Cell
ISSN (Online):1878-3686
Published Online:08 May 2017
Copyright Holders:Copyright © 2017 Elsevier Inc.
First Published:First published in Cancer Cell 31(5): 612-613
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record